Search

Your search keyword '"Willekens, Christophe"' showing total 7 results
Start Over Author "Willekens, Christophe" Publisher wiley
7 results on '"Willekens, Christophe"'

1. When monoclonal gammopathy‐associated chronic neutrophilic leukemia is a reactive process distinct from a clonal myeloproliferative neoplasm: Lessons from mistakes

Author

Willekens, Christophe, primary, Chahine, Claude, additional, Dragani, Matteo, additional, Khalife‐Hachem, Sabine, additional, Bigenwald, Camille, additional, Rossignol, Julien, additional, Castilla‐Llorente, Cristina, additional, Danu, Alina, additional, Michot, Jean‐Marie, additional, Saada, Veronique, additional, Cotteret, Sophie, additional, Marzac, Christophe, additional, Renneville, Aline, additional, Plo, Isabelle, additional, Broutin, Sophie, additional, Bosselut, Nelly, additional, Cassinat, Bruno, additional, Lazarovici, Julien, additional, Droin, Nathalie, additional, and De Botton, Stephane, additional

Published
2023
Full Text
View/download PDF

2. Attenuated cytarabine, etoposide, dexamethasone plus rituximab (R‐Mini‐CYVE) regimen for patients with relapsed or refractory B‐cell non–Hodgkin’s lymphoma not eligible for intensive chemotherapy

Author

Abdayem, Pamela, primary, Ibrahim, Nathalie, additional, El Dakdouki, Yolla, additional, Willekens, Christophe, additional, Ghez, David, additional, A. Rouche, Julia, additional, Dartigues, Peggy, additional, Desmaris, Romain, additional, Danu, Alina, additional, Rossignol, Julien, additional, Lazarovici, Julien, additional, Fermé, Christophe, additional, Ribrag, Vincent, additional, and Michot, Jean M., additional

Published
2021
Full Text
View/download PDF

3. High‐dose cyclophosphamide for hard‐to‐treat patients with relapsed or refractory B‐cell non‐Hodgkin's lymphoma, a phase II result

Author

Michot, Jean‐Marie, primary, Annereau, Maxime, additional, Danu, Alina, additional, Legoupil, Clémence, additional, Bertin, Louis, additional, Chahine, Claude, additional, Achab, Nadia, additional, Antosikova, Anna, additional, Cerutti, Ariane, additional, Rossignol, Julien, additional, Ghez, David, additional, Willekens, Christophe, additional, Dartigues, Peggy, additional, Lazarovici, Julien, additional, Lemare, Francois, additional, and Ribrag, Vincent, additional

Published
2020
Full Text
View/download PDF

4. Bendamustine and rituximab combination in the management of chronic lymphocytic leukemia-associated autoimmune hemolytic anemia: A multicentric retrospective study of the French CLL intergroup (GCFLLC/MW and GOELAMS)

Author

Quinquenel, Anne, primary, Willekens, Christophe, additional, Dupuis, Jehan, additional, Royer, Bruno, additional, Ysebaert, Loic, additional, Guibert, S. De, additional, Michallet, Anne-Sophie, additional, Feugier, Pierre, additional, Guieze, Romain, additional, Levy, Vincent, additional, and Delmer, Alain, additional

Published
2015
Full Text
View/download PDF

5. Minimal residual disease monitoring int(8;21) acute myeloid leukemia based onRUNX1-RUNX1T1fusion quantification on genomic DNA

Author

Duployez, Nicolas, primary, Nibourel, Olivier, additional, Marceau-Renaut, Alice, additional, Willekens, Christophe, additional, Helevaut, Nathalie, additional, Caillault, Aurélie, additional, Villenet, Céline, additional, Celli-Lebras, Karine, additional, Boissel, Nicolas, additional, Jourdan, Eric, additional, Dombret, Hervé, additional, Figeac, Martin, additional, Preudhomme, Claude, additional, and Renneville, Aline, additional

Published
2014
Full Text
View/download PDF

6. Prognostic value of PINI index in patients with multiple myeloma

Author

Dupire, Sophie, primary, Wemeau, Mathieu, additional, Debarri, Houria, additional, Pascal, Laurent, additional, Hivert, Benedicte, additional, Willekens, Christophe, additional, Boyle, Eileen, additional, Manier, Salomon, additional, Béatrice, Thielemans, additional, Onraed, Brigitte, additional, Faucompré, Jean-Luc, additional, Hennache, Bernadette, additional, Dumontet, Charles, additional, Facon, Thierry, additional, and Leleu, Xavier, additional

Published
2012
Full Text
View/download PDF

7. Molecular Landscape of Therapy-related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers.

Author

Khalife-Hachem S, Saleh K, Pasquier F, Willekens C, Tarabay A, Antoun L, Grinda T, Castilla-Llorente C, Duchmann M, Quivoron C, Auger N, Saada V, Delaloge S, Leary A, Renneville A, Antony-Debre I, Rosselli F, De Botton S, Salviat F, Marzac C, and Micol JB

Abstract

Definition of therapy-related myeloid neoplasms (TRMN) is only based on clinical history of exposure to leukemogenic therapy. No specific molecular classification combining therapy-related acute myeloid leukemia and therapy-related myelodysplastic syndromes has been proposed. We aimed to describe the molecular landscape of TRMN at diagnosis, among 77 patients with previous gynecologic and breast cancer with a dedicated next-generation sequencing panel covering 74 genes. We investigated the impact of clonal hematopoiesis of indeterminate potential-associated mutations (CHIP-AMs defined as presence at TRMN stage of mutations described in CHIP with a frequency >1%) on overall survival (OS) and the clinical relevance of a modified genetic ontogeny-based classifier that categorized patients in 3 subgroups. The most frequently mutated genes were TP53 (31%), DNMT3A (19%), IDH1/2 (13%), NRAS (13%), TET2 (12%), NPM1 (10%), PPM1D (9%), and PTPN11 (9%). CHIP-AMs were detected in 66% of TRMN patients, with no impact on OS. Yet, patients with CHIP-AM were older and had a longer time interval between solid tumor diagnosis and TRMN. According to our modified ontogeny-based classifier, we observed that the patients with TP53 or PPM1D mutations had more treatment lines and complex karyotypes, the "MDS-like" patients were older with more gene mutations, while patients with "De novo/pan-AML" mutations were younger with more balanced chromosomal translocations. Median OS within each subgroup was 7.5, 14.5, and 25.2 months, respectively, with statistically significant difference in multivariate analysis. These results support the integration of cytogenetic and molecular markers into the future TRMN classification to reflect the biological diversity of TRMN and its impact on outcomes., (Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results